Physician profile
Brittany E Thomas
NPI 1851123749
$1,979.75
in general payments reported to CMS, 2019-2025
30 companies · $1,850 in 2025
The $1,850 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $130 · 2025: $1,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $427.54 | 2025 | Enhertu, Tagrisso, Imfinzi |
| Janssen Biotech, INC. | $277.87 | 2025 | Rybrevant, Carvykti, Talvey |
| Geron Corporation | $198.64 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $121.17 | 2025 | Monoferric |
| Merck Sharp & Dohme LLC | $113.05 | 2025 | Keytruda |
| Eisai INC. | $100.49 | 2024 | |
| Caris Mpi, INC. | $73.22 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $66.15 | 2025 | Itovebi |
| Daiichi Sankyo INC. | $62.37 | 2025 | Enhertu, Datroway |
| Cumberland Pharmaceuticals, INC. | $50.99 | 2025 | Sancuso |
| Pharmaessentia USA Corporation | $45.68 | 2025 | Besremi |
| Jazz Pharmaceuticals INC. | $44.95 | 2025 | |
| Incyte Corporation | $41.92 | 2025 | Monjuvi, Jakafi |
| Ironshore Pharmaceuticals INC. | $29.06 | 2024 | |
| Syndax Pharmaceuticals, INC. | $28.66 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $28.31 | 2025 | Vyloy |
| Medtronic, INC. | $25.37 | 2025 | Kyphon Express II Kyphopak Tray |
| Ipsen Biopharmaceuticals, INC | $24.52 | 2025 | Onivyde, Somatuline Depot |
| Adaptive Biotechnologies Corporation | $23.43 | 2025 | Clonoseq |
| Sobi, INC | $21.24 | 2025 | |
| Agios Pharmaceuticals, INC. | $19.59 | 2025 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $19.33 | 2025 | Rolvedon |
| Pharming Healthcare, INC. | $19.08 | 2025 | Ruconest |
| Alnylam Pharmaceuticals INC. | $18.90 | 2025 | Givlaari |
| Aveo Pharmaceuticals, INC. | $17.50 | 2025 | |
| Collegium Pharmaceutical, INC. | $17.13 | 2025 | Belbuca |
| Alexion Pharmaceuticals, INC. | $16.89 | 2025 | Ultomiris |
| Glaxosmithkline, LLC. | $16.23 | 2025 | Jemperli, Zejula |
| Array Biopharma INC | $15.96 | 2025 | Braftovi, Lorbrena, Mektovi |
| Genzyme Corporation | $14.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.